Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial

Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children

(2020) Jing Pan et al.   LEUKEMIA

Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory t‐cell acute lymphoblastic leukemia/lymphoma. the campus‐all study.

(2020) Anna Candoni et al.   AMERICAN JOURNAL OF HEMATOLOGY

Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990–2015

(2020) Ardine M. J. Reedijk et al.   LEUKEMIA

Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia

(2019) David T Teachey et al.   LANCET ONCOLOGY

Early and late hematologic toxicity following CD19 CAR-T cells

(2019) Shalev Fried et al.   BONE MARROW TRANSPLANTATION

Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL

(2019) Jing Pan et al.   BLOOD

An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies

(2018) Matthew L Cooper et al.   LEUKEMIA

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor

(2017) K H Chen et al.   LEUKEMIA

A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies

(2015) M. Mamonkin et al.   BLOOD

A systematic review of transfusion-associated graft-versus-host disease

(2015) I. Kopolovic et al.   BLOOD

Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study

(2015) Ching-Hon Pui et al.   LANCET ONCOLOGY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience

(2013) P Jain et al.   LEUKEMIA

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)

(2009) D. I. Marks et al.   BLOOD

Poor Outcome for Children and Adolescents With Progressive Disease or Relapse of Lymphoblastic Lymphoma: A Report From the Berlin-Frankfurt-Muenster Group

(2009) Birgit Burkhardt et al.   JOURNAL OF CLINICAL ONCOLOGY

Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation

(2009) Ching-Hon Pui et al.   NEW ENGLAND JOURNAL OF MEDICINE